Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials

Sha’Shonda L. Revels; Jay M. Lee

首页> 外文期刊>Journal of Thoracic Disease >Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials

【24h】

Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials

机译：靶向VEGF受体（VEGFR）的酪氨酸激酶抑制（TKI）中的抗血管生成治疗（NSCLC）：靶向VEGF受体（VEGFR）：III期临床试验的透视

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Annually, there are over 200,000 lung cancer diagnoses in the United States (1). Only about 15% of patients are diagnosed with early stage disease (1). The prognosis of those with advanced disease, such as stage IIIB or stage IV, is dismal and less than 5% (1). The standard of care includes platinum based systemic therapy combinations. However, treatments are shifting toward newer targeted and small molecule therapies to improve outcomes among patients with advanced non-small cell lung cancer (NSCLC).

机译：每年，美国有超过20万人的肺癌诊断（1）。只有大约15％的患者被诊断出患有早期疾病（1）。具有晚期疾病的人的预后，如阶段IIIB或阶段IV，令人沮丧，低于5％（1）。护理标准包括基于铂的全身疗法组合。然而，治疗朝向更新的靶向和小分子疗法转化，以改善高级非小细胞肺癌（NSCLC）患者的结果。

著录项

来源
《Journal of Thoracic Disease》 |2018年第2期|共页
作者
Sha’Shonda L. Revels; Jay M. Lee;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation [J] . Yan Xiangtao, Wang Huijuan, Li Peng, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019,第期

机译：单独或与低丰度突变的先进非小细胞肺癌（NSCLC）组合单独使用表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）的疗效。
2. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第2016期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
3. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第4期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. EGFR in Early Non-Small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial. [D] . Lara-Guerra, Humberto. 2011

机译：早期非小细胞肺癌中的EGFR：新辅助试验中酪氨酸激酶抑制作用。
6. Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials [O] . Sha’Shonda L. Revels, Jay M. Lee 2018

机译：非鳞状非小细胞肺癌（NSCLC）的靶向VEGF受体（VEGFR）的酪氨酸激酶抑制（TKI）的抗血管生成治疗：III期临床试验的观点
7. 481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy [O] . K. Nakagawa, J.C.-H. Yang, K. Park, 2016

机译：481tip Checkmate 722：在EGFR酪氨酸激酶抑制剂（Tki ）治疗

Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials

摘要

著录项

相似文献

相关主题

期刊订阅